retatrutide shot A New Obesity Drug Delivered Surgery-Level Weight Loss in Clinical Trials Retatrutide for weight loss: Study

It is time to correct this once and for all

The post Insurance companies scrambling to support need for GLP-1 drugs appeared first on Insurance News | InsuranceNewsNet.

Reasons for low levels of initiation and long-term use of AOMs may include reluctance of public health and medical organizations to recognize obesity as a disease, lack of reimbursement, provider inexperience, and misperceptions about the efficacy and safety of available treatments

Retatrutide is designed to activate these three receptors in a way that affects appetite, fullness, glucose control and metabolism

The risk is not toxicity

Phase 2 trial data showed mean body weight reductions of approximately 24% over 48 weeks at the highest dose in adults with obesity without type 2 diabetes